Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novelinsulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH.Circius Therapeutics focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States.

Therapeutics

Pharmaceutical

Biotechnology

Cirius Therapeutics

Cirius Therapeutics' headquarters in Kalamazoo, MI, United States

Bob Baltera

Angeline Shashlo

Jerry Colca

Stephen A. Harrison

Doug Morton

Michael Jandernoa

David Van Andel

Robert L. Zerbe

Jack Dixon

Jorge Plutzky

Daniel Bloomfield

Brian Finck

Roger Ulrich

Description

People

Jobs